Clinical Trial Update: An Open Label Study to Examine the Effects of a High-Fat Meal and Particle Size on the Pharmacokinetics of Orally Administered GSK2118436 in Subjects With BRAF Mutation Positive Tumor [Phase 1]

View source ↗

Summary

This completed Phase 1 open-label study assessed how a high-fat meal and drug particle size influence the pharmacokinetics of GSK2118436 (dabrafenib) in subject…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• GSK2118436 (dabrafenib) (dabrafenib)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Cancer | Phase 1 | Status: COMPLETED